Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US2021106583A1
Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
KR20200085868A
Immunoproteasome inhibitors
KR20200090810A
Immunoproteasome inhibitors
EP3571208A1
Immunoproteasome inhibitors
EP3478273A1
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
MX2018001350A
Processes for preparing an fgfr inhibitor.
US2018305350A1
Tyrosine kinase inhibitors
CR20170593A
THYROSINE-KINASE INHIBITORS
EP3298011A1
Quinolone derivatives as fibroblast growth factor receptor inhibitors
EP3236943A1
Compositions for ileo-jejunal drug delivery
AU2015371254A1
Site specific dosing of a BTK inhibitor
SG11201704808VA
Treatment of pemphigus
US2018208589A1
LMP7 inhibitors
US2016368908A1
Benzimidazole derivatives as RLK and ITK inhibitors
MX2016010754A
Salts and solid form of a btk inhibitor.
AU2015214328A1
Quinolone derivatives as Fibroblast Growth Factor Receptor Inhibitors
EP2994470A1
Pyrido[2,3-d]pyrimidine derivatives as fibroblast growth factor inhibitors
KR20150085068A
Azaindole derivatives as jak3 inhibitors
US2014142099A1
Purinone Derivatives as Tyrosine Kinase Inhibitors
